The nation of Zimbabwe has declined a major American health deal worth $367m (272 million pounds) spanning five years due to Washington's request for sensitive biological samples.
This rejection was revealed after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa believed the agreement was "skewed".
An official spokesperson later stated that the United States was seeking biological samples for research and commercial purposes while was not willing to guarantee the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for further talks to secure a deal agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were filed about the security of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump stated its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
Based on statements, Sixteen African countries have to date signed these new agreements, representing more than $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, with no equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"In essence, our nation would supply the basic resources for medical research without any certainty that the final treatments would be accessible to our population if a new disease outbreak emerge."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral deals were undermining frameworks already established through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing system created to manage potential pandemics.
"This mechanism is designed to guarantee that when a nation contributes its data, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to create them."
These objections regarding the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing dialogue with our US partners on how future collaboration could be arranged in a way that honours the sovereignty and dignity of both nations."
Medical Community Response
Medical experts expressed it acknowledged the government's concerns, but urged that negotiations must proceed since a large portion of the country's Aids initiatives depended on external financing.
"If technical issues exist, including those relating to data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," the group said.
The situation emphasises the ongoing debate between accepting much-needed international aid and protecting national sovereignty in an ever more interconnected world.